(0.12%) 4 582.25 points
(0.21%) 36 086 points
(0.01%) 15 988 points
(-0.29%) $75.74
(-0.86%) $2.78
(0.52%) $2 068.00
(1.91%) $25.78
(0.61%) 941.60
(-0.03%) 0.918
(-0.46%) 10.75
(-0.30%) 0.790
(0.00%) 89.98
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
Today's Volume | 1.46M |
Average Volume | 798 146 |
Market Cap | 65.08M |
EPS | $0 ( 2023-11-01 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-65.60 |
Last 94 transactions |
Buy: 4 075 585 | Sell: 5 548 482 |
Volume Correlation
Surface Oncology Inc Correlation
10 Most Positive Correlations | |
---|---|
ISO | 0.841 |
ARQT | 0.833 |
ALLO | 0.827 |
ALVR | 0.818 |
DVAX | 0.818 |
BGFV | 0.816 |
ENNV | 0.815 |
LQDT | 0.805 |
ALZN | 0.805 |
CARE | 0.804 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Surface Oncology Inc Correlation - Currency/Commodity
Surface Oncology Inc Financials
Annual | 2022 |
Revenue: | $30.00M |
Gross Profit: | $30.00M (100.00 %) |
EPS: | $-1.170 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.460 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.340 |
Q4 | 2022 |
Revenue: | $30.00M |
Gross Profit: | $30.00M (100.00 %) |
EPS: | $-0.350 |
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
AboutLive Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators